Tiziana Life Sciences strengthens intranasal foralumab development with Renaissance Lakewood partnership
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a clinical-stage biotechnology company focused on immunomodulation therapies, has announced a strategic partnership with Renaissance Lakewood LLC, a leading ... Read More
Tiziana Life Sciences to launch phase 2 trial of Foralumab in Covid-19
Tiziana Life Sciences said that it plans to launch a phase 2 clinical trial to evaluate the nasal administration of Foralumab in moderate to severe ... Read More